Evidence map›Paper›PMID 33508897›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2021

[Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].

Haoyang Li, Jinghui Wang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Haoyang LiDepartment of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute,
Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Jinghui WangDepartment of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute,
Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Beijing Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy, in particular immune checkpoint inhibitors, has significantly improved the survival outcomes of advanced lung cancer patients and changed the treatment mode of lung cancer. In this article, we reviewed the mechanism of immunotherapy, the clinical trials that changed treatment guidelines, the important biomarkers, immune-related adverse events, and descripted the future of immunotherapy of advanced non-small cell lung cancer.
.

Indexed as

ImmunotherapyAnimalsAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsAntineoplastic Agents, ImmunologicalImmune checkpoint inhibitorsImmunotherapyLung neoplasms

Identifiers

PMID33508897
PMCPMC7936086
OpenAlexW3121641884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.